倍欣治疗2型糖尿病100例疗效观察  

Observation of Therapeutic Efficacy of Basen on 100 cases with Type-Ⅱ Diabetes

作　　者：黄昭穗[1] 刘开渊[1] 陈志忠[1] 黄胜立[1] 欧阳万青[1] 黄海蓉[1] 

机构地区：[1]中国人民解放军第九五医院内科,351100

出　　处：《福建医药杂志》2002年第1期12-14,共3页Fujian Medical Journal

摘　　要：目的　探讨倍欣对 2型糖尿病降糖作用的疗效。方法　将单纯饮食控制或加用磺脲类药物治疗不满意的2型糖尿病人 198例 ,随机分为倍欣组 10 0例和二甲双胍组 98例 ,疗程为 8WK。结果与结论　倍欣和二甲双胍对空服血糖均有显著性下降 ,总有效率分别为 86 .0 %、 90 .8% ,但两药降低幅度无统计学意义 P>0 .0 5 ;而倍欣对餐后 2 h血糖的疗效高于二甲双胍 ,总有效率分别为 94 .0 %、 81.6 3% (P<0 .0 1) ;两药均能明显降低 GHb AIc,但倍欣疗效高于二甲双胍 P<0 .0 5 ;两种药物不刺激胰岛素分泌 。Objective To evaluate the therapeutic efficacy of Basen on 100 patients with Type Ⅱ Diabetes.Materials and methods One hundred and ninty eight cases with Type Ⅱ Diabetes,who had been treated either with controlled diet management or medicines,were randomly divided into two groups,Basen group(n=100)and metfornin(Diabex)group(n=98).The observational period was 8 weeks.Results The both Basen and Metfornin(Diabex)were significantly reduced the level of blood glucose in the fasting state(total efficacy rate was 86 0% and 90 8%,respectively).But the decreased amplitutd of blood gulcose level at 2h postmeal in Basen group was more larger than those in Metfornin group(total efficacy rate was 94 0% and 81 63%,respectively;P<0 01).Conclusion Both Basen and Metfornin were effectively reduced GHbAIc,while the results of Basen treatment was more efficient.Moreover,both two medicine do not stimulate the secreation of insulin and do not affect to functions of liver and renal.

关 键 词：Ⅱ型糖尿病 倍欣 二甲双胍 血糖 药物治疗 比较 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]